

biotech companies tackling today’s biggest challenges.
Revvity Drug Discovery Mixer: Science, Posters & Cocktails
Join us for an evening of science, networking, and cocktails at MBC Biolabs! Explore Revvity solutions for drug discovery, engage with scientific posters, and connect with fellow researchers while enjoying some refreshments.
Attendees will have the opportunity to explore research posters from Revvity, as well as scientists and startups working across a range of areas, including:
Oliver Sun, Ph.D. – Reasoned Therapeutics
Poster: SynLlama: Generating Synthesizable Molecules and Their Analogs with Large Language ModelsIris Lam – Rejoovenate Bio
Rejoovenate Bio is discovering compounds that rejuvenate the ovarian cellular environment, with the goal of extending female reproductive longevity and improving egg quality with age.Amina Khan – Sculpta
Sculpta is a science-first biotech startup developing RNA-based neurotherapeutics to modulate disease-associated biological pathways with greater precision and efficacy.Marissa Lee – Taudia
Taudia is developing ultrasensitive protein detection technologies, including a low-cost, scalable 5-plex assay for simultaneously detecting pTau-217, Aβ40, Aβ42, NfL, and GFAP in human plasma samples.Sophie Li – Silas Lab, Gladstone Institutes
Poster: Decoding Phage Susceptibility in Wild E. coli: Path to a Successful Infection.Description: O-antigen is a major barrier to phage infection in wild Escherichia coli. To test this directly, we disrupted O-antigen biosynthesis in 34 wild E. coli strains from the ECOR collection and challenged them with eight model coliphages (T2–T7, λ, and P1). O-antigen removal increased phage susceptibility by 10³–10⁸-fold across ~70% of phage-host combinations, with full infection observed in ~40% of interactions, demonstrating that O-antigen is the dominant determinant of phage susceptibility across diverse wild strains. The remaining phage-host combinations exhibited intermediate infection yet displayed consistent phage-specific plaquing profiles across diverse strains, suggesting that only a limited number of intracellular defenses are at play once the O-antigen barrier is removed. We applied genome-wide RB-TnSeq to identify these defenses, and preliminary analyses revealed shared intracellular defenses across five ECOR ΔwecA mutant libraries challenged with phage T5. Together, these findings suggest that phage susceptibility in wild E. coli may be governed by a limited number of major defenses, providing a framework for more rational phage selection in therapeutic applications.
This is a great opportunity to connect with researchers, entrepreneurs, and innovators from across the Bay Area life science ecosystem.
We welcome poster presentations! If you'd like to share your work, please contact Estelle N'garwate at Estelle.Ngarwate@revvity.com.
biotech companies tackling today’s biggest challenges.